Quantifying risk of bleeding with post-MI anti-thrombotics

In this retrospective analysis of 40,812 patients hospitalized with an MI, researchers analyzed the risk of bleeding-related hospitalizations according to different anti-thrombotic medication regimens (combinations of ASA, clopidogrel, and vitamin K antagonists). After a mean follow up of 1.3 years, the overall risk of bleeding-related hospitalizations was 5%. The annual risk for all monotherapy groups, the ASA+clopidogrel, and the ASA+vitamin K antagonist groups were between 3-5%, but was 12% for the clopidogrel + vitamin K and the triple therapy groups. The most common non-fatal bleeding was GI, and the most fatal bleeding was related to femoral pseudoaneurysms. This study helps quantify the risks of bleeding-related re-hospitalizations in patients being discharged on anti-thrombotic combinations (abstract)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment